Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Alphatec Spine Reaches Milestone Of OsseoFix Adoption
Alphatec Holdings, Inc. (Nasdaq: ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, today announced that, as of June 1, 2009, over 115 patients in eight European countries have been treated with the OsseoFix™ Spinal Fracture Reduction System, the Company"s innovative product for the treatment of vertebral compression fractures. The first European training session was held at the University of Vienna in mid-December 2008. The first shipments of OsseoFix products into Europe occurred at the end of December 2008. Don't forget to buy zoloft online no prescription.

New Once-daily Treatment For Type 2 Diabetes
A new treatment for Type 2 diabetes has hit the headlines today. Liraglutide (Victoza), a once-daily injectable treatment for Type 2 diabetes, is pharmaceutical company Novo Nordisk"s latest brain child.

generic viagra online


News of the day
HSE Warns Employers To Safeguard Employees After Worker Suffers Double-Fracture To Finger, UK
The Health and Safety Executive (HSE) is warning employers to ensure they have adequate safeguards in place to prevent access to dangerous parts of their machinery. This warning follows HSE"s prosecution of Metal Containers Ltd (formerly trading as Greif UK Ltd) after an employee"s one finger was broken in two places and another injured in the unguarded rotating part of a chained conveyor.
Nutrition

Meda: FDA Approval For Onsolis Anticipated During Summer 2009

Since August 2008, Meda (STO:MEDAA) and BioDelivery Sciences International (BDSI) have worked in close collaboration with the U.S. Food and Drug Administration (FDA) to complete the final requirement of a Risk Evaluation and Mitigation Strategy (REMS) program for Onsolis (fentanyl - treatment of breakthrough cancer pain). Last Friday, FDA"s review Division informed Meda and BDSI that they had reached agreement with the REMS for Onsolis, but that the FDA needed some additional time to complete the final senior level sign off. Meda therefore expects Onsolis to be approved by the FDA during summer, which could enable a fourth quarter 2009 launch, as previously anticipated. MEDA AB (publ) is a leading international specialty pharma company. The company specialises in marketing and pharmaceutical development in late clinical stage. Acquisitions and long-term partnerships drive the company"s strategy. Meda is represented by its own organizations in about 40 countries. Meda"s products are sold in 120 countries worldwide. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange Stockholm. Find out more, visit http://www.meda.se. MEDA AB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009